ANAB

AnaptysBioA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

Current thesis

The bull case is that the completed spin removes structural uncertainty, leaves ANAB with a simpler royalty-management story, and eventually allows investors to value Jemperli and imsidolimab economics plus aggressive capital returns more cleanly once initial post-spin disclosures arrive [#8-K-2026-04-20] [#PR-2026-03-27].

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -2.6.

What can break

Any underwhelming capital return execution could weaken the core standalone royalty-equity thesis.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $56.00 · Bull $68.00 · Bear $38.00

Data freshness

Prices

As of 2026-06-02

Fundamentals

As of 2026-06-01 • Vendor: Data Vendor v1

Scores

As of 2026-06-02 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-21 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-06-02

Supporting evidence

What

Grade A · Constructive

Confidence Medium · Net Neutral

Target $70.36

Why

Momentum95 · Δ7d -2.6

Value41 · Δ7d +0.1

Sentiment53 · Δ7d +14.4

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Momentum · See technicals

Momentum

34% active weight

Current posture

7d trendSoftening

Δ7d

-2.6

Δ21d

-5.1

Value

32% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

+0.2

Sentiment

33% active weight

Current posture

7d trendImproving

Δ7d

+14.4

Δ21d

+29.5

Why this grade

Composite grade A. Momentum 94.7 / Value 41.1 / Sentiment 53.4

Fundamentals (TTM)

As of 2026-06-01

Market Cap

$1.55B

Beta

0.36

Shares Out

27.69M

P/E (TTM) · Derived

-10.9

P/S (TTM)

7.06

P/FCF (TTM) · Derived

-11.43

Rev YoY

+154.3%

EPS YoY

+145.8%

Gross Margin

Op Margin

-16.9%

Net Debt

-$31.95M

Current Ratio

8.68

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology